Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07252050 · ClinicalTrials.gov registry record · Phase 1
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
A Phase 1 study, sponsored by Arkansas Children's Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07252050 is a Phase 1 study that is actively recruiting participants, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 24 participants.
The verdict
NCT07252050, a Phase 1 study, is actively recruiting participants, sponsored by Arkansas Children's Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.
Interventions
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2029-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07252050
The ClinicalTrials.gov registry entry for NCT07252050 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arkansas Children's Hospital Research Institute, which has 97 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT07252050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07252050 about?
NCT07252050 is a clinical study titled "Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease". This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and trea...
What is the current status of trial NCT07252050?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-06-08. Estimated completion is 2029-11-19.
What interventions are being tested in trial NCT07252050?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07252050?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.